Hua joined BBOT in December 2024 as Vice President of Translational Medicine. She brings more than two decades of experience in drug and diagnostic discovery and product development. Before joining BBOT, Hua served as Senior Vice President of Translational Medicine at Zai Lab, where she led biomarker strategies across all early- and late-stage development programs. She also played a critical role in expanding Zai Lab’s global pipeline. Prior to Zai Lab, Hua was the Chief Operating Officer and Head of Precision Medicine at Adagene, where she played a pivotal role in the company’s successful IPO in February 2021. Her expertise contributed to the development and approval of seven oncology drugs during her tenure at Navigate, a Novartis subsidiary. Hua also spent multiple years at Premier Research, Prometheus, and ten years at Pfizer, leading multiple programs preclinically and clinically.

Hua received her MD from Anhui Medical University, PhD in Cancer Biology at Wayne State University, and MS in Biostatistics at Sun-Yet-Sen University of Medical Sciences.